Tech Company Financing Transactions

Skyhawk Therapeutics Funding Round

Skyhawk Therapeutics closed a $8 million Seed funding round on 1/24/2018. Investors included Alexandria Venture Investments and private investors.

Transaction Overview

Company Name
Skyhawk Therapeutics
Announced On
1/24/2018
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Seed
Investors

Alexandria Venture Investments (Lead Investor) (Catherine Nuccio)

private investors (Lead Investor) (Timothy Disney)

private investors (Andrew Bedford)

Proceeds Purpose
Proceeds of the financing will advance Skyhawk's portfolio of specific and selective small molecules that initially target RNA exon skipping, which drives a set of 50+ diseases that include both broad-based neurological conditions and previously undruggable oncogenes in cancer.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
35 Gatehouse Dr.
Waltham, MA 02451
USA
Phone
(617) 858-0041
Website
www.skyhawktx.com
Email Address
[email protected]
Overview
Skyhawk's founders are leading scientists in the development of small molecule therapeutics that correct RNA expression. Our proprietary technology enables the rational design of small molecules that target the RNA splicing process. We are now developing drug candidates for cancer, neurological disease, and rare disease.
Profile
Skyhawk Therapeutics LinkedIn Company Profile
Social Media
Skyhawk Therapeutics Company Twitter Account
Company News
Skyhawk Therapeutics News
Facebook
Skyhawk Therapeutics on Facebook
YouTube
Skyhawk Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chairman
Friedrich Metzger
  Friedrich Metzger LinkedIn Profile  Friedrich Metzger Twitter Account  Friedrich Metzger News  Friedrich Metzger on Facebook
Chief Executive Officer
William Haney
  William Haney LinkedIn Profile  William Haney Twitter Account  William Haney News  William Haney on Facebook
Chief Financial Officer
Gary Martell
  Gary Martell LinkedIn Profile  Gary Martell Twitter Account  Gary Martell News  Gary Martell on Facebook
Chief Scientific Officer
Kathleen McCarthy
  Kathleen McCarthy LinkedIn Profile  Kathleen McCarthy Twitter Account  Kathleen McCarthy News  Kathleen McCarthy on Facebook
Vice President
Michael Luzzio
  Michael Luzzio LinkedIn Profile  Michael Luzzio Twitter Account  Michael Luzzio News  Michael Luzzio on Facebook
Vice President
Sergey Paushkin
  Sergey Paushkin LinkedIn Profile  Sergey Paushkin Twitter Account  Sergey Paushkin News  Sergey Paushkin on Facebook
VP - Finance
Maura McCarthy
  Maura McCarthy LinkedIn Profile  Maura McCarthy Twitter Account  Maura McCarthy News  Maura McCarthy on Facebook

 

 

Browse more venture capital transactions:

Prev: 1/24/2018: Stem venture capital transaction
Next: 1/24/2018: HNI Healthcare venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to report on tech company VC transactions. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.